A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier
0301 basic medicine
Medicine (General)
cervical cancer
Mice, Nude
antisense lncrna of mdc1
Apoptosis
Cell Cycle Proteins
03 medical and health sciences
R5-920
Drug Delivery Systems
International Journal of Nanomedicine
Cell Movement
Cations
Cell Line, Tumor
Animals
Humans
Molecular Targeted Therapy
Original Research
Adaptor Proteins, Signal Transducing
Cell Proliferation
Drug Carriers
Mice, Inbred BALB C
0303 health sciences
Magnetic Phenomena
oxaliplatin
targeted therapy
3. Good health
Gene Expression Regulation, Neoplastic
Oxaliplatin
Drug Liberation
Liposomes
magnetic thermosensitive cationic liposome
Female
DOI:
10.2147/ijn.s258316
Publication Date:
2021-02-12T14:02:55Z
AUTHORS (13)
ABSTRACT
Background: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA MDC1 (MDC1-AS) Cervical cancer cells evaluate efficiency this its antitumor effects on cancer. Methods: Thermosensitive liposomes were prepared using thin-film hydration method. The OXA MDC1-AS vectors loaded into system, in vitro release activity, regulating MDC1, cytotoxicity, vivo activity determined. Results: system had desirable targeted delivery efficacy, release, MDC1. Codelivery enhanced inhibition cervical cell growth vivo, compared with single delivery. Conclusion: can be applied combined chemotherapy gene therapy Keywords: liposome, oxaliplatin, therapy,
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (46)
CITATIONS (33)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....